Cryogenicist

We proudly congratulate Prof. Dr. Zhan Zhang on receiving the Research Excellence Award at the Cryogenicist Global Awards. This prestigious honor recognizes outstanding contributions, innovation, and global impact in cryogenic science and technology. Prof. Zhang’s work continues to advance the frontiers of research and inspire excellence across the international scientific community. 🌍🔬 Visit: cryogenicist.com Nomination Link: https://cryogenicist.com/award-nomina... Contact:  admin@cryogenicist.com #ProfDrZhanZhang #ResearchExcellenceAward #CryogenicistGlobalAwards #CryogenicScience #ScientificExcellence #GlobalRecognition #InnovationInScience #ResearchLeadership #STEMAwards

  The failure of the PSLV-C62 mission is not merely a setback for a launch vehicle or for the Indian Space Research Organisation. It is a warning signal about deeper, structural weaknesses in India’s space ecosystem at a time when space has become central not just to economic growth, but to military power and strategic autonomy. As space increasingly shapes outcomes across land, sea, air, cyber and information domains, India’s relative slippage carries consequences far beyond prestige. Five failures in seven years — but the real concern lies elsewhere This is the fifth ISRO failure in the past seven years. While launch failures occur even in the most advanced space programmes, what distinguishes India’s case is the broader stagnation visible across the space value chain. Despite being the world’s fourth-largest economy, India is losing ground to established space powers — the US, China, Russia, the EU and Japan — across all three segments of space activity: upstream (satellite cons...

  AstraZeneca Pharma India and Sun Pharmaceutical Industries have formed a new partnership to expand access to Sodium Zirconium Cyclosilicate (SZC), a key therapy for managing hyperkalaemia in patients with chronic kidney disease and heart failure. The collaboration aims to increase nationwide availability through dual-brand marketing. Dual-Brand Strategy to Expand Market Reach Under the agreement, both companies will promote and distribute SZC independently. AstraZeneca will market the drug under the brand Lokelma, while Sun Pharma will introduce it as Gimliand. This dual-brand model is expected to strengthen penetration across diverse healthcare settings without altering AstraZeneca’s ownership of the molecule. Intellectual Property and Regulatory Control Retained AstraZeneca will continue to hold intellectual property rights, marketing authorisation and the import licence for SZC in India. The company emphasised that the partnership would help scale up access to an essential the...